Public Employees Retirement System of Ohio Has $32,000 Holdings in Seer, Inc. (NASDAQ:SEER)

Public Employees Retirement System of Ohio decreased its position in shares of Seer, Inc. (NASDAQ:SEER) by 33.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,020 shares of the company’s stock after selling 8,024 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Seer were worth $32,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of SEER. Palumbo Wealth Management LLC lifted its holdings in shares of Seer by 15.1% during the 3rd quarter. Palumbo Wealth Management LLC now owns 122,292 shares of the company’s stock worth $241,000 after acquiring an additional 16,001 shares during the period. AQR Capital Management LLC acquired a new position in Seer during the second quarter valued at approximately $30,000. American Century Companies Inc. lifted its stake in Seer by 42.1% during the second quarter. American Century Companies Inc. now owns 61,752 shares of the company’s stock worth $104,000 after purchasing an additional 18,302 shares during the last quarter. Point72 DIFC Ltd bought a new stake in Seer during the second quarter worth $35,000. Finally, Quadrature Capital Ltd boosted its holdings in shares of Seer by 301.7% in the 3rd quarter. Quadrature Capital Ltd now owns 57,088 shares of the company’s stock valued at $112,000 after purchasing an additional 42,875 shares in the last quarter. 75.20% of the stock is currently owned by institutional investors and hedge funds.

Seer Stock Performance

Seer stock opened at $2.31 on Monday. Seer, Inc. has a 52 week low of $1.51 and a 52 week high of $2.63. The stock has a market capitalization of $136.21 million, a P/E ratio of -1.78 and a beta of 1.58. The stock has a fifty day moving average of $2.24 and a 200-day moving average of $1.93.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.